| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| ln Vitro |
Orexin A (human, rat, mouse) TFA has a high affinity for OX1R and OX2R, with an IC50 of 38 nM and an EC50 of 34 nM in the [Ca2+]i transient assay[1].
|
|---|---|
| ln Vivo |
Orexin A (human, rat, mouse) TFA (3-30 mg/kg; intravenous injection; pre-test 5 minutes) significantly prolonged the response latency in mice at intravenous doses of 10 mg/kg and 30 mg/kg, from 24.8±2.0 s in the carrier control group to 35.0±3.7 s and 45.7±4.5 s, respectively [2]. Orexin A (human, rat, mouse) TFA (3, 10 and 30 mg/kg; intravenous injection) administered immediately before benzoquinone (PPQ) administration prolonged the latency of the first PPQ-induced skin contraction, from 357.4±35.2 s in the carrier control group to 500.3±31.2 s in the 10 mg/kg dose group and 594.5±5.5 s in the 30 mg/kg dose group [2].
|
| Animal Protocol |
Animal/Disease Models:Female mice (Carrageenan-induced thermal hyperalgesia test in mice [2])
Dose: 3, 10 and 30 mg/kg Route of Administration: Intravenous injection; 5 minutes before the test Experimental Results: 10 and 30 mg/kg doses significantly prolonged the latency of the response. |
| References |
| Molecular Formula |
C152H243N47O44S4.XC2HF3O2
|
|---|---|
| Molecular Weight |
3561.10 (free base)
|
| Related CAS # |
Orexin A-13C18,15N3 (human, rat, mouse) TFA; Orexin A (human, rat, mouse); Orexin A (human, rat, mouse) acetate; Orexin A-13C5,15N (human, rat, mouse) TFA
|
| Sequence |
{Glp}-PLPDCCRQKTCSCRLYELLHGAGNHAAGILTL-NH2 (Disulfide bridge: Cys6-Cys12, Cys7-Cys14)
|
| SequenceShortening |
{Glp}-PLPDCCRQKTCSCRLYELLHGAGNHAAGILTL-NH2 (Disulfide bridge: Cys6-Cys12, Cys7-Cys14)
|
| Appearance |
White to off-white solid
|
| Synonyms |
Hypocretin-1 (human, rat, mouse) TFA
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: 请将本产品存放在密封保护的环境中，避免受潮。 |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ~100 mg/mL (with sonication)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
